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Abstract
Background Melanoma incidence and mortality rates are increasing worldwide within the white population. Clinical
and histological factors have been usually used for the prognosis and assessment of the risk for melanoma.
Objectives The aim of the study was to describe the clinical and histopathological features of the cutaneous
melanoma (CM) in the Latvian population, to test the association between melanoma features and patient survival,
and to assess the time trends for melanoma incidence.
Methods We undertook a descriptive, retrospective analysis of archive data of 984 melanoma patients treated at
the largest oncological hospital of Latvia, Riga East University Hospital Latvian Oncology Centre (LOC), between
1998 and 2008. Cox proportional hazards model was used to analyse patient survival and autoregressive models
were applied to detect trends in melanoma incidence over time for various categories of melanoma.
Results The study showed a significant ascending trend in melanoma incidence in Latvia during the time period
from 1998 to 2008 (ß = 1.83, 95% CI = 1.15-2.91, P = 0.011). Nodular melanoma was the most common tumour
subtype with a frequency of 39.2%. Ulceration was present in 45.2% of melanomas. The mean Breslow thickness
was 6.0 mm (6.8 mm) and no significant decline in median Breslow thickness was observed during the study period
(P = 0.609). A better overall prognosis was detected for females in comparison with males (HR = 1.49; 95%
CI = 1.22–1.81; P < 0.001).
Conclusions There is a steady increase in melanoma incidence in Latvia with the majority of melanomas diagnosed
at late stages with poor prognosis for survival.
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Introduction
Cutaneous melanoma (CM) is the most serious form of skin can-
cer with a high potential to develop metastases. It comprises only
4% of all skin cancers, but has the highest mortality rate amongst
all malignant skin tumours.1 The incidence of CM has increased
substantially within Caucasian population in the last few dec-
ades.2,3 Moreover, it is one of the most common types of cancer
occurring in young adults4 making this type of cancer the most
serious in terms of the number of years of life lost. Several interna-
tional studies have shown that the clinical and histological features
of CM are very important for assessing the course and prognosis
of the disease.2,5 No comprehensive study of melanoma epidemi-
ology or histopathological features has been previously conducted
in Latvia except a study of the head and neck melanoma that
pointed out the prevalence of late diagnosed melanomas.6 The
aim of our study was to analyse a considerably broader spectrum
of melanoma patients from the Riga East University Hospital Lat-
vian Oncology Center (LOC) to assess the characteristics and
trends of the CM in Latvia.
Materials and methods
We analysed the archive data of all CM patients treated at the
LOC, the largest oncological hospital in the country with approxi-
mately 80% of all melanomas referred, in the period between the
January 1st, 1998 and the December 31st, 2008. For each patient
information about age, gender, tumour localization and subtype,
Breslow thickness of the melanoma, ulceration, presence of pig-
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mentation, predominant cell type and clinical stage was recorded.
Only patients with confirmed histology of primary CM were
included in the study. CM relapse patients and patients with skin
metastases with an unknown primary tumour localization were
excluded. The total number of patients retained in the study was
984. If a patient had had more than one primary melanoma only
the first melanoma was analysed. Each patient was followed up
until October 2011, and the overall survival was determined using
the Cancer Registry data.
The above mentioned melanoma characteristics were compared
amongst male and female patients as well as between two different
age groups; younger and older than 63, which was the calculated
median age. The difference in characteristics amongst these groups
was assessed by a Pearson’s chi-squared test. If the number of
patients in one of the subgroups was small, Fisher’s exact test was
used instead of a chi-squared test. If the association with a charac-
teristic was significant and the characteristic studied was a factor
with three or more categories, pairwise comparisons between vari-
ous categories were made to elucidate the major source of the dis-
crepancy. Pairwise analysis was done either by a chi-squared test
or a Fisher’s exact test if the number of observations in one of the
categories was small.
Difference between groups of patients in terms of Breslow thick-
ness and age, both being continuous variables not following the
normal distribution, was assessed by the non-parametric Mann–
Whitney test.
Gender, age and melanoma characteristics were studied for their
impact upon patients survival rate. The overall survival was
analysed by the Cox proportional hazards model. When studying
a melanoma characteristic with three or more categories, multi-
variate analysis was performed, otherwise a univariate model was
used. The significance of the impact of a factor upon survival was
assessed by the logrank test providing the P-value for the whole
univariate or multivariate model. The hazard ratio for each value
of a factor together with its 95% confidence interval was calculated
as well. For this purpose, the R function coxph from the survival
package by Terry Therneau7 was used. Kaplan–Meier curves were
drawn for separate categories of patients. The curves were esti-
mated by the function survfit from the survival package. Through-
out all survival models, the time was measured in months.
The changes in melanoma incidence as well as changes of
median Breslow thickness over time were analysed by the auto-
regressive model of the first order. The model has the form
Xt = l + bÆXt-1 + et where Xt is the incidence at time t, l is a
constant intercept, b measures the dependence between the inci-
dence rate at neighbouring time units and et is the error term.
We are particularly interested in testing whether b is significantly
different from 1 and whether incidences form an ascending
(b > 1) or descending (b < 1) trend. Both the overall time trend
and trends within subcategories of patients and melanoma char-
acteristics were studied. The models were fitted by the least
squares regression in R using the function arma from the tseries
package by Adrian Trapletti and Kurt Hornik.8 P-values measur-
ing the significance of the difference of b from 1 were reported
together with an estimation of b and its 95% confidence inter-
val. The incidence of melanoma was measured as the number of
new cases per 100 000 inhabitants (crude rate) and adjusted by
age using Latvian and European standard populations for each
gender separately by direct method. For each stratum of age and
gender, an estimate of the Latvian population provided by the
Central Bureau of Statistics was used for the normalization. The
size of European standard population for each age group was
obtained from the data base of the National Cancer Institute.
The time was measured in years.
Results
In the studied cohort, the mean standardized incidence of mela-
noma was 6.5 per 100 000 inhabitants. An ascending trend in the
number of diagnoses was observed over time; by 2008, the inci-
dence had increased by 2.69 cases per 100 000 compared with
1998 (ß = 1.83, 95% CI = 1.15–2.91, P = 0.011). The increase in
melanoma cases was particularly evident for males and changed
from 2.52 per 100 000 inhabitants in 1998 to 3.96 in 2008
(ß = 1.86, 95% CI = 1.11–3.12, P = 0.019). For females, the
increase in melanoma cases was slightly lower and changed from
2.59 per 100 000 in 1998 to 3.85 in 2008 thus remaining insignifi-
cant (ß = 1.26, 95% CI = 0.77–2.06; P = 0.353) (Fig. 1).
In total, there were 984 melanoma patients included in the
study, and only five patients (0.5%) had developed several primary
melanomas during the study period. The distribution of melanoma
characteristics in association with gender is depicted in Table 1.
There was a correlation between gender of the patient and the
localization of melanoma (P < 0.001). Female patients were domi-
nating amongst the patients with melanoma localization on either
lower or upper limbs, whereas male patients had an excess of mel-
anomas on the trunk (Table 1). P-values of all pairwise compari-
sons with melanoma frequency on trunk were highly significant
(Table 2).
Figure 1 Trends of the melanoma incidence from 1998 to 2008.
Separate curves are drawn for the total incidence and the inci-
dence of melanoma for male and female patients. P-value show-
ing the significance of a non-constant time trend of a curve is
indicated next to the colour definition of the curve.
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Breslow thickness of melanoma was slightly higher in males
(6.2 mm ± 6.5 mm) compared with females (5.9 mm ± 7.0 mm)
with distribution of tumour thickness being rather similar in both
groups (P = 0.186) (Table 1). Likewise, ulcerated melanomas were
more widespread amongst males than females; however, these dif-
ferences were not statistically significant (Table 1). The association
of the age with different melanoma characteristics was analysed
next. For this purpose, the patients were divided into two age
groups according to the median age (£63 and >63 years), and the
age distribution across these groups was assessed for each clinical
or histopathological feature (Table 3). The characteristic of mela-
noma that was the most associated with age was localization
(P < 0.001). In particular, the predominance of the head and neck
melanomas amongst the elderly patients (>63 years) was revealed
(Table 3). Pairwise comparisons of head and neck melanoma with
all other localizations yielded notable P-values (Table 2). Amela-
notic and ulcerated melanomas were also more widespread
amongst the elderly (P = 0.013 and P < 0.001 respectively) and
tended to be thicker according to the Breslow thickness
(P < 0.001) (Table 3).
The analysis of the clinical stage distribution showed that the
majority of tumours were stage II melanomas. Clinical stage IIC,
IIB and IIA melanomas were found in 20.1% (198), 14.6% (144)
and 13.3% (131) of patients respectively. There were no differences
in clinical stage distribution neither between genders nor in associ-
ation with age (data not shown).
The difference in overall survival was assessed for the patients
exhibiting different clinical and histopathological features of the
Table 1 Distribution of melanoma characteristics and patient’s age within the analysed cohort: total distribution, distribution for
female and male patients
Total n (%)
n = 984
Females
n (%)n = 640
Males
n (%)n = 344
P-value*
Age (years)
Median 63.4 64.2 62.6 0.282
Mean (±SD) 61.3 (±15.3) 61.6 (±15.6) 60.7 (±14.7)
Lesion site
Lower limbs 320 (32.5) 265 (41.4) 55 (16.0) <0.001
Upper limbs 158 (16.1) 116 (18.1) 42 (12.2)
Head and neck 123 (12.5) 84 (13.1) 39 (11.3)
Trunk 376 (38.2) 172 (26.9) 204 (59.3)
Genital region 7 (0.7) 3 (0.5) 4 (1.2)
CM subtype
Superficial spreading melanoma 40 (4.1) 23 (3.6) 17 (4.9) 0.528#
Nodular melanoma 386 (39.2) 246 (38.4) 140 (40.7)
Lentigo maligna melanoma 15 (1.5) 12 (1.9) 3 (0.9)
In situ 7 (0.7) 5 (0.8) 2 (0.6)
NA 536 (54.5) 354 (55.3) 182 (52.9)
Breslow thickness, mm
Median 4.0 4.0 4.0 0.801
Mean (±SD) 6.0 (±6.8) 5.9 (±7.0) 6.2 (±6.5)
Ulceration
Present 445 (45.2) 283 (44.2) 162 (47.1) 0.305
Absent 275 (28.0) 186 (29.1) 89 (25.9)
NA 264 (26.8) 171 (26.7) 93 (27.0)
Pigment
Present 797 (80.9) 525 (82.0) 272 (79.1) 0.780
Absent 94 (9.6) 60 (9.4) 34 (9.9)
NA 93 (9.5) 55 (8.6) 38 (11.0)
Cell type
Epitheloid 520 (52.9) 334 (52.2) 186 (54.1) 0.207#
Balloon 24 (2.4) 13 (2.0) 11 (3.2)
Spindle 144 (14.6) 105 (16.4) 39 (11.3)
Nevoid 12 (1.2) 9 (1.4) 3 (0.9)
Mixed 125 (12.7) 80 (12.5) 45 (13.1)
NA 159 (16.2) 99 (15.5) 60 (17.4)
*To assess group differences, v2 tests were used and data marked by # were obtained using Fisher’s exact test, except for age and Breslow thick-
ness where Mann–Whitney test was applied; SD, Standard deviation; NA, Not applicable.
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melanoma. The Kaplan–Meier curves showed a better overall
prognosis for females than for males (HR = 1.49; 95% CI = 1.22–
1.81; P < 0.001) (Fig. 2a). The primary tumour localization did
not play a significant role for survival (P = 0.197), except for
males with melanoma on limbs (HR = 2.29; 95% CI = 1.67–3.14;
P < 0.001) (Fig. 2b).
The subtype of melanoma plays a significant role in survival
(P < 0.001). As expected, patients with a superficial spreading
melanoma had better prospects than patients with a nodular mela-
noma (HR = 4.14; 95% CI = 1.83–9.33; P < 0.001) (Fig. 2c). As
there were many cases with a missing data on melanoma subtype,
we included them as a separate category in the model: the overall
association with survival remained the same (P < 0.001), and the
missing cases showed a hazard ratio that was somewhat closer to
the nodular melanoma cases (HR = 3.78; 95% CI = 1.68–8.52).
Similarly, the correlation between the Breslow thickness of the
tumour and the survival rate was significant (HR = 1.04; 95%
CI = 1.03–1.05; P < 0.001).
The association between the ulceration and survival was also
revealed: survival was better for patients without ulceration
(HR = 0.39; 95% CI = 0.30–0.51; P < 0.001) (Fig. 2d). Inclusion
of the tumours with missing ulceration information as a separate
category in the model did not change the result (P < 0.001), and
the hazard ratio of the missing category was approximately average
of the remaining ratios (HR = 0.61; 95% CI = 0.48–0.76) indicat-
ing no biases in missing information towards any particular cate-
gory. Pigmented tumours showed brighter prospects than
amelanotic melanomas (HR = 1.91; 95% CI = 1.43–2.55;
P < 0.001) (Fig. 2e). There was no correlation between the pre-
dominant cell type of melanoma and a patient’s survival
(P = 0.747) (Fig. 2f). In contrast, the association between the clin-
ical stage and the survival was again clearly evident (P < 0.001).
For the analysed study period, a decrease of the median age in
males (from 67.2 to 60.3 years) and an increase of the median age
in females (from 59.8 to 65.83 years) were observed, although
these changes were not statistically significant (P = 0.624 and
P = 0.577 respectively) (Fig. 3a,b). A significant increase in the
number of melanomas localized on the trunk was discovered.
(ß = 2.21; 95% CI = 1.50–3.23; P < 0.001). The number of mela-
nomas with other localizations has been growing as well, although
these changes were not significant (Fig. 4a). No significant changes
in incidence were observed for various melanoma subtypes, not
even for the most common subtype, the nodular melanoma
(Fig. 4b). Similarly, the median Breslow thickness did not change
significantly over time (ß = 0.86; 95% CI = 0.48–1.54; P = 0.609)
(Fig. 3c).
Table 3 Distribution of melanoma characteristics and patient’s
gender for elderly (> 63 years) and younger (£ 63 years) patients
£63 years
n (%)n = 506
>63 years
n (%)n = 478
P-value*
Gender
Female 318 (62.8) 322 (67.4) 0.156
Male 188 (37.2) 156 (32.6)
Lesion site
Lower limbs 167 (33.0) 153 (32.1) <0.001
Upper limbs 77 (15.2) 81 (16.9)
Head and neck 37 (7.3) 86 (18.0)
Trunk 220 (43.5) 156 (32.6)
Genital region 5 (1.0) 2 (0.4)
CM subtype
Superficial
spreading
melanoma
26 (5.1) 14 (2.9) 0.161#
Nodular melanoma 185 (36.6) 201 (42.1)
Lentigo maligna
melanoma
9 (1.8) 6 (1.3)
In situ 3 (0.6) 4 (0.8)
NA 283 (55.9) 253 (52.9)
Breslow thickness, mm
Median 3.8 5.0 <0.001
Mean (±SD) 5.4 (±6.2) 6.6 (±7.4)
Ulceration
Present 197 (38.9) 248 (51.9) <0.001
Absent 165 (32.6) 110 (23.0)
NA 144 (28.5) 120 (25.1)
Pigment
Present 418 (82.6) 379 (79.3) 0.013
Absent 36 (7.1) 58 (12.1)
NA 52 (10.3) 41 (8.6)
Cell type
Epitheloid 270 (53.4) 250 (52.3) 0.087#
Spindle 65 (12.9) 79 (16.5)
Ballon 17 (3.4) 7 (1.5)
Nevoid 8 (1.6) 4 (0.8)
Mixed 58 (11.5) 67 (14.0)
NA 88 (17.4) 71 (14.9)
*To assess group differences, v2 tests were used and data marked by
#were obtained using Fisher’s exact test, except for Breslow thickness
where Mann–Whitney test was applied; SD, Standard deviation; NA, not
applicable.
Table 2 Pairwise comparison of melanoma localisations in
terms of the correlation with gender and age
Gender Head and
neck
Trunk Lower
limbs
Upper
limbs
Genital
region
Age
Head and neck <0.001 0.001 0.419 0.219#
Trunk <0.001 <0.001 <0.001 1.000#
Lower limbs <0.001 0.110 0.023 0.022#
Upper limbs 0.002 0.048 0.540 0.096#
Genital region 0.036# 0.705# 0.453# 0.277#
*The diagonal of the matrix separates the results of two different
analyses. The upper right triangle of the matrix contains P-values of the
chi-squared test measuring association of a particular localization with
gender, whereas the lower left triangle contains the P-values of the
correlation with age. In cells marked by #Fisher’s exact test was used.
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A significant increase of non-ulcerated melanomas (Fig. 4c)
(ß = 2.50; 95% CI = 1.65–3.80; P < 0.001) was revealed. A
decrease in amelanotic melanomas, however, insignificant was
detected (Fig. 4d). There were no alterations of clinical stage dis-
tribution except for stage IA, where the increase was detected
(ß = 2.20; 95% CI = 1.25–3.89; P = 0.006 (Fig. 4e).
(a) (b)
(c) (d)
(e) (f)
Figure 2 Kaplan–Meier curves for differences in survival: (a) by gender, (b) by gender in case of melanoma localization on the limbs,
(c) by melanoma subtype, (d) by presence of ulceration, (e) by presence of pigment and (f) by cell type involved in the formation of
melanoma. The P-value in each panel shows the difference in survival between all depicted categories and corresponds to the log-
rank test applied to the Cox proportional hazards model.
(a) (b)
(c)
Figure 3 Box plots showing the distribution of age at the time of melanoma diagnosis and Breslow thickness by year: (a) age at
diagnosis for females, (b) age at diagnosis for males and (c) Breslow thickness.
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Discussion
Our study showed a significant increase in melanoma incidence
based on patient data obtained from the largest oncological hospi-
tal in the country LOC during the period from 1998 until 2008.
The observed increase from 5.1 new cases per 100 000 inhabitants
in 1998 to 7.8 new cases in 2008 (Figure 1) is consistent with a
similar trend in Latvian Cancer registry as well as in other Euro-
pean countries. The observed predominance of females affected by
CM is typical for countries like Latvia with a relatively low inci-
dence of melanoma. In countries with higher melanoma incidence
such as Australia, male and female melanoma incidence rates are
similar or even higher in males.5 Several studies have demon-
strated that females have a higher survival rate than males.2,9 Our
data also indicate a better survival rate for females despite the fact
that the mean age at the time of diagnosis is higher in females than
in males. We cannot provide a clear explanation for this observa-
tion. There might be a correlation with the differences in anatomi-
cal sites of the primary CM. According to Freedman et al.10 there
is no association with menopausal status, use of hormone replace-
ment therapy, age at first birth or oral contraceptive use.
Several international studies have shown that the mean age at
the time of diagnosis lies between 53.7 and 59.0 years.11,12 The
mean age at the time of melanoma onset in our study was
61.3 years, thus higher. This could be explained by the fact that
melanoma patients in Latvia are generally diagnosed at later stages,
which would also explain the comparatively worse survival rates.
Furthermore, tanning beds in Latvia became broadly available only
in the last two decades. It could mean that patients included in
this study had accumulated less of an artificial sun exposure dur-
ing their life, and therefore have a later onset of melanoma. How-
ever, the association between the use of tanning beds and the age
of melanoma onset should be still clarified.
It has been previously shown that melanoma patients tend to
develop a second primary melanoma;13 however, only 0.5% of the
patients in our study had developed a second primary melanoma.
This number is low compared with other studies,13–15 which have
reported the incidence rate of multiple primary melanomas to lie
between 0.5 and 8.6%. In 29–59% of cases, the next primary mela-
noma develops during the first year after the initial diagnosis.13,15
A part of these melanomas develop later in life, and there is a
chance that a second primary melanoma is not diagnosed at all
unless regular skin examinations are performed by dermatologists.
In accordance with other studies, we found that the most fre-
quent localization of the tumour was the trunk as well as the head
and the neck in males and limbs in females.5,9,16 Like Ferrari
(a) (b)
(c) (d)
(e)
Figure 4 Trends of the melanoma incidence from 1998 to 2008 by various melanoma characteristics: (a) lesion site, (b) melanoma
subtype, (c) ulceration, (d) pigment and (e) clinical stage. Time trends for each category of melanoma are depicted as a separate
curve. P-value measuring the significance of a non-constant time trend of a curve is indicated next to the colour definition of the
curve.
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et al.,11 we have also shown the predominace of the head and neck
melanoma in elderly patients. All localizations in males have been
associated with a worse survival rate than for females.17 We have
replicated this finding only for males diagnosed with a melanoma
on their limbs.
According to several authors,18,19 superficial spreading mela-
noma is the most frequent tumour subtype. In our study, nodular
tumours were the most frequent subtype, showing lower survival
rate when compared with superficial spreading melanoma. It has
been reported16,20 that male patients have a tumour histopathol-
ogy associated with worse prognosis than females and that nodular
tumours occur more frequently in males. We observed more males
than females with nodular melanomas, but the numbers had no
statistical significance, which could be explained by the predomi-
nance of nodular tumours in our cohort. In contrast to the most
studies,3 melanomas in situ were also very rarely observed in our
study indicating delayed melanoma diagnosis in Latvia. Surpris-
ingly, there were no acral lentiginous melanomas in the studied
cohort, probably due to the large numbers of cases with unidenti-
fied tumour subtype especially for melanomas localized on feet
and hands (data not shown).
Our findings underline the importance of Breslow thickness
and ulceration for the prognosis of the disease. An increase in
tumour depth correlates with a poorer prospect and is one of the
most important prognostic factors for melanoma.21,22 Although
the mean Breslow thickness has declined between 1998 and 2008
(data not shown), the median tumour thickness has not changed
over time and remains high (6.00 mm) when compared with
other European countries where the mean thickness of melanoma
is 0.80–2.24 mm.3,5,23 We confirmed significantly higher survival
rates for patients without ulcerated melanomas. In our study, we
did not analyse the ulceration as a risk factor for metastasis, but
according to Balch et al.9 ulcerated tumours show higher potential
to metastasize if compared with those with the same Breslow
thickness but without epidermal ulceration. Patients with tumour
ulceration, especially males, have worse survival rates than patients
of the same gender but without ulceration. Amelanotic melanomas
comprised 9.6% of all melanoma cases, which is slightly more than
the reported rates which lie between 1.8% and 8.1%.24 Patients
with pigmented melanomas had a better survival rate than patients
with amelanotic tumours. This could be explained by the difficul-
ties in detecting amelanotic melanomas, which can lead to a
delayed diagnosis24 as well as by the fact that the most common
presentation of amelanotic melanoma is of nodular variety.23
Moreover, the growth rate for both nodular and amelanotic mela-
nomas has been shown to be greater in comparison with other
melanomas.25,26 In concordance with other studies,27 epithelioid
cells were the most frequent cells involved in primary melanoma
formation in our study. We did not reveal any association between
the cell type of CM and a patient’s survival.
We observed an increase in stage IA patients, which could imply
a recent improvement in the diagnosis of melanoma. However,
the majority of melanoma cases are still diagnosed at late stages in
Latvia. This could be due to the melanoma screening not being a
mandatory or routine procedure in clinics, especially the full body
skin examination. Furthermore, despite various attempts to raise
melanoma awareness through informative campaigns, many
patients ignore sun protective behaviour28 or suspicious lesions
and are afraid to consult medical doctors.
One of the limitations of our study is that the analysed CM
patient data were obtained from a large referral centre and cannot
be entirely attributed to the whole Latvian population. However,
LOC is the largest oncological hospital in the country, where the
majority of melanomas are treated. A similar approach to the data
collection has been used previously.29 Moreover, the observed
increase in melanoma incidence in LOC was similar to the trends
in Cancer Registry data. Some of the interpretations were ham-
pered by the large proportion of cases with missing melanoma
subtype and ulceration status. The survival rate of melanoma
patients with an unknown tumour subtype was quite close to the
nodular melanoma cases that form the majority of the cohort thus
indicating that many uncharacterised melanomas could actually
be nodular. Patients with a missing ulceration status are roughly
average of the remaining cases in terms of survival indicating no
biases towards any particular category. In concordance with our
findings, it was reported by De Vries et al.30 that there are fewer
superficial spreading melanomas in the Eastern Europe. Eastern
and Western Europe Cancer Registries were compared in their
study. However, the interpretation of their data was also limited
by the large proportion of cases with missing information on
melanoma stage and histopathology parameters.
In conclusion, our study showed a steady increase in melanoma
incidence in Latvia with a high percentage of delayed tumours. It was
also shown that this delay leads to a poor survival and prognosis. To
increase the efficiency ofmelanoma diagnostics as well as to improve
the outcome ofmelanoma in Latvia,more attention has to be paid to
theimportanceofeducationalcampaigns,developmentofmelanoma
preventionprogramsandabettercooperationbetweengeneralpracti-
tioners,dermatologistsandoncologists.
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